REGENXBIO Inc. (RGNX) Covered Calls
You can sell covered calls on REGENXBIO Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for RGNX (prices last updated Fri 4:16 PM ET):
REGENXBIO Inc. (RGNX) Stock Quote | ||||||
---|---|---|---|---|---|---|
Last | Change | Bid | Ask | Volume | P/E | Market Cap |
9.63 | -1.51 | 9.65 | 10.00 | 1.3M | - | 0.6 |
Covered Calls For REGENXBIO Inc. (RGNX) | ||||||
---|---|---|---|---|---|---|
Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
Dec 20 | 10 | 2.30 | 7.70 | 29.9% | 303% | |
Jan 17 | 10 | 2.00 | 8.00 | 25.0% | 143% | |
Subscribers get access to the full covered call chain, and more features. |
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501 for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111 to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121 for the treatment of neurological symptoms of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV technology platform to other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Top 10 Open Interest For Dec 20 Expiration | Top 5 High Yield | |||||
---|---|---|---|---|---|---|
1. | NVDA covered calls | 6. | QQQ covered calls | 1. | SAVA covered calls | |
2. | SPY covered calls | 7. | XLF covered calls | 2. | RKLB covered calls | |
3. | EEM covered calls | 8. | KWEB covered calls | 3. | LUNR covered calls | |
4. | FXI covered calls | 9. | TLT covered calls | 4. | NMRA covered calls | |
5. | IWM covered calls | 10. | KRE covered calls | 5. | CRVS covered calls |
Want more examples? RGLS Covered Calls | RGP Covered Calls